A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (≤6-month of treatment) a reduction in the number of migraine headache days and improved patients’ functioning. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Camporeale, Angelo, Kudrow, David, Sides, Ryan, Wang, Shufang, Van Dycke, Annelies, Selzler, Katherine J., Stauffer, Virginia L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234796/
https://www.ncbi.nlm.nih.gov/pubmed/30413151
http://dx.doi.org/10.1186/s12883-018-1193-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234796/
https://www.ncbi.nlm.nih.gov/pubmed/30413151
http://dx.doi.org/10.1186/s12883-018-1193-2

Ejemplares similares